These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 36578194

  • 1. Efficacy and Safety of Infliximab in Intestinal Behçet's Disease: A Multicenter, Phase 3 Study (BEGIN).
    Cheon JH, Kim HS, Han DS, Kim SK, Shin SJ, Kim JS, Ye BD, Song GA, Lee Y, Kim Y, Lee Y, Kim WH, BEGIN Study Group.
    Gut Liver; 2023 Sep 15; 17(5):777-785. PubMed ID: 36578194
    [Abstract] [Full Text] [Related]

  • 2. Mucosal Healing at 14 Weeks Predicts better Outcome in Low-dose Infliximab Treatment for Chinese Patients with Active Intestinal Behcet's Disease.
    Zou J, Ji DN, Shen Y, Guan JL, Zheng SB.
    Ann Clin Lab Sci; 2017 Mar 15; 47(2):171-177. PubMed ID: 28442519
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness and safety of adalimumab in patients with intestinal Behçet's disease: a real-world prospective observational study in South Korea.
    Yu J, Shin SJ, Park YJ, Kim HW, Lee BI, Ye BD, Kim GT, Kim SK, Kim JS, Kim YH, Jeong S, Cheon JH.
    BMC Gastroenterol; 2023 Dec 19; 23(1):449. PubMed ID: 38114956
    [Abstract] [Full Text] [Related]

  • 4. Long-Term Outcomes and Predictors of Sustained Response in Patients with Intestinal Behcet's Disease Treated with Infliximab.
    Zou J, Ji DN, Cai JF, Guan JL, Bao ZJ.
    Dig Dis Sci; 2017 Feb 19; 62(2):441-447. PubMed ID: 28044230
    [Abstract] [Full Text] [Related]

  • 5. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
    Sugimura N, Mizoshita T, Sugiyama T, Togawa S, Miyaki T, Suzuki T, Tanida S, Kataoka H, Sasaki M.
    Dig Liver Dis; 2019 Jul 19; 51(7):967-971. PubMed ID: 30872086
    [Abstract] [Full Text] [Related]

  • 6. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study.
    Hibi T, Hirohata S, Kikuchi H, Tateishi U, Sato N, Ozaki K, Kondo K, Ishigatsubo Y.
    Medicine (Baltimore); 2016 Jun 19; 95(24):e3863. PubMed ID: 27310969
    [Abstract] [Full Text] [Related]

  • 7. Predictors of infliximab refractory intestinal Behçet's syndrome: A retrospective cohort study from the Shanghai Behçet's syndrome database.
    Bao HF, Hou CC, Ye B, Zou J, Luo D, Cai JF, Shen Y, Guan JL.
    Mod Rheumatol; 2023 Jan 03; 33(1):207-216. PubMed ID: 34932796
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease.
    Naganuma M, Sakuraba A, Hisamatsu T, Ochiai H, Hasegawa H, Ogata H, Iwao Y, Hibi T.
    Inflamm Bowel Dis; 2008 Sep 03; 14(9):1259-64. PubMed ID: 18393375
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease.
    Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Hanami K, Tanaka Y.
    Mod Rheumatol; 2011 Apr 03; 21(2):184-91. PubMed ID: 21052764
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy of infliximab in patients with intestinal Behçet's disease refractory to conventional medication.
    Kinoshita H, Kunisaki R, Yamamoto H, Matsuda R, Sasaki T, Kimura H, Tanaka K, Naganuma M, Maeda S.
    Intern Med; 2013 Apr 03; 52(17):1855-62. PubMed ID: 23994973
    [Abstract] [Full Text] [Related]

  • 12. Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet's disease.
    Miyagawa I, Nakano K, Iwata S, Nakayamada S, Saito K, Hanami K, Fukuyo S, Kubo S, Kawabe A, Miyazaki Y, Tanaka Y.
    Arthritis Res Ther; 2019 Jun 22; 21(1):151. PubMed ID: 31228955
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and predictor of anti-TNFα agents in patients with intestinal Behçet's disease.
    Miyazaki H, Watanabe D, Okamoto N, Tokunaga E, Ku Y, Takenaka H, Hoshi N, Ooi M, Kodama Y.
    BMC Gastroenterol; 2022 Mar 28; 22(1):149. PubMed ID: 35346067
    [Abstract] [Full Text] [Related]

  • 14. Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.
    Park J, Cheon JH.
    Gut Liver; 2018 Nov 15; 12(6):623-632. PubMed ID: 29788675
    [Abstract] [Full Text] [Related]

  • 15. Baricitinib for the treatment of intestinal Behçet's disease: A pilot study.
    Liu J, Yu X, Wang Z, Liu W, Liu X, Wang X, Zhang M, Zhao Y, Zhang F, Yang H, Zheng W.
    Clin Immunol; 2023 Feb 15; 247():109241. PubMed ID: 36702180
    [Abstract] [Full Text] [Related]

  • 16. Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet's disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter study.
    Lee SB, Hong HS, Lee CK, Lee BI, Kim S, Koh SJ, Yu H, Park JB, Hwang SW, Ye BD, Yang SK, Park SH, IBD Research Group of the Korean Association for the Study of Intestinal Diseases (KASID).
    Korean J Intern Med; 2023 Sep 15; 38(5):661-671. PubMed ID: 37491721
    [Abstract] [Full Text] [Related]

  • 17. Remission induction, maintenance, and endoscopic outcome with oral 5-aminosalicylic acid in intestinal Behçet's disease.
    Kinoshita H, Nishioka H, Ikeda A, Ikoma K, Sameshima Y, Ohi H, Tatsuno M, Kouyama J, Kawamoto C, Mitsui T, Tamura Y, Hashimoto Y, Nishio M, Ogashiwa T, Saigusa Y, Maeda S, Kimura H, Kunisaki R, Koike K.
    J Gastroenterol Hepatol; 2019 Nov 15; 34(11):1929-1939. PubMed ID: 31017728
    [Abstract] [Full Text] [Related]

  • 18. Update on the Treatment of Behcet's Disease of the Small Bowel with Biologic Agents.
    Park Y, Cheon JH.
    Curr Gastroenterol Rep; 2020 Mar 19; 22(5):24. PubMed ID: 32193746
    [Abstract] [Full Text] [Related]

  • 19. Anti-TNF-α agents for refractory intestinal Behçet's disease: case series and meta-analysis.
    Zhan S, Liu C, Li N, Li T, Tian Z, Zhao M, Wu D, Chen M, Zeng Z, Zhuang X.
    Therap Adv Gastroenterol; 2022 Mar 19; 15():17562848221116666. PubMed ID: 36082178
    [Abstract] [Full Text] [Related]

  • 20. Adalimumab for the treatment of Japanese patients with intestinal Behçet's disease.
    Tanida S, Inoue N, Kobayashi K, Naganuma M, Hirai F, Iizuka B, Watanabe K, Mitsuyama K, Inoue T, Ishigatsubo Y, Suzuki Y, Nagahori M, Motoya S, Nakamura S, Arora V, Robinson AM, Thakkar RB, Hibi T.
    Clin Gastroenterol Hepatol; 2015 May 19; 13(5):940-8.e3. PubMed ID: 25245624
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.